High-Dose Opioid Prescribing in Individuals with Acute Pain: Assessing the Effects of US State Opioid Policies

Overview

Journal J Gen Intern Med

Publisher Springer

Specialty General Medicine

Date 2024 Jul 19

PMID 39028403

Authors

Ashley C Bradford

Thuy Nguyen

Lucy Schulson

Andrew Dick

Sumedha Gupta

Kosali Simon

Bradley D Stein

Affiliations

Soon will be listed here.

Abstract

Background: How state opioid policy environments with multiple concurrent policies affect opioid prescribing to individuals with acute pain is unknown.

Objective: To examine how prescription drug monitoring programs (PDMPs), pain management clinic regulations, initial prescription duration limits, and mandatory continued medical education affected total and high-dose prescribing.

Design: A county-level multiple-policy difference-in-difference event study framework.

Subjects: A total of 2,425,643 individuals in a large national commercial insurance deidentified claims database (aged 12-64 years) with acute pain diagnoses and opioid prescriptions from 2007 to 2019.

Main Measures: The total number of acute pain opioid treatment episodes and number of episodes containing high-dose (> 90 morphine equivalent daily dosage (MEDD)) prescriptions.

Key Results: Approximately 7.5% of acute pain episodes were categorized as high-dose episodes. Prescription duration limits were associated with increases in the number of total episodes; no other policy was found to have a significant impact. Beginning five quarters after implementation, counties in states with pain management clinic regulations experienced a sustained 50% relative decline in the number of episodes containing > 90 MEDD prescriptions (95 CIs: (Q5: - 0.506, - 0.144; Q12: - 1.000, - 0.290)). Mandated continuing medical education regarding the treatment of pain was associated with a 50-75% relative increase in number of high-dose episodes following the first year-and-a-half of enactment (95 CIs: (Q7: 0.351, 0.869; Q12: 0.413, 1.107)). Initial prescription duration limits were associated with an initial relative reduction of 25% in high-dose prescribing, with the effect increasing over time (95 CI: (Q12: - 0.967, - 0.335). There was no evidence that PDMPs affected high-dose opioids dispensed to individuals with acute pain. Other high-risk prescribing indicators were explored as well; no consistent policy impacts were found.

Conclusions: State opioid policies may have differential effects on high-dose opioid dispensing in individuals with acute pain. Policymakers should consider effectiveness of individual policies in the presence of other opioid policies to address the ongoing opioid crisis.

References

Jones C, Paulozzi L, Mack K . Sources of prescription opioid pain relievers by frequency of past-year nonmedical use United States, 2008-2011. JAMA Intern Med. 2014; 174(5):802-3. PMC: 6688495. DOI: 10.1001/jamainternmed.2013.12809. View

Alam A, Gomes T, Zheng H, Mamdani M, Juurlink D, Bell C . Long-term analgesic use after low-risk surgery: a retrospective cohort study. Arch Intern Med. 2012; 172(5):425-30. DOI: 10.1001/archinternmed.2011.1827. View

Brummett C, Waljee J, Goesling J, Moser S, Lin P, Englesbe M . New Persistent Opioid Use After Minor and Major Surgical Procedures in US Adults. JAMA Surg. 2017; 152(6):e170504. PMC: 7050825. DOI: 10.1001/jamasurg.2017.0504. View

Schroeder A, Dehghan M, Newman T, Bentley J, Park K . Association of Opioid Prescriptions From Dental Clinicians for US Adolescents and Young Adults With Subsequent Opioid Use and Abuse. JAMA Intern Med. 2018; 179(2):145-152. PMC: 6439650. DOI: 10.1001/jamainternmed.2018.5419. View

Cramer J, Gunaseelan V, Hu H, Bicket M, Waljee J, Brenner M . Association of State Opioid Prescription Duration Limits With Changes in Opioid Prescribing for Medicare Beneficiaries. JAMA Intern Med. 2021; 181(12):1656-1657. PMC: 8353574. DOI: 10.1001/jamainternmed.2021.4281. View

Denis C, Morales K, Wu Q, Metzger D, Cheatle M . Association Between Diagnoses of Chronic Noncancer Pain, Substance Use Disorder, and HIV-Related Outcomes in People Living With HIV. J Acquir Immune Defic Syndr. 2019; 82 Suppl 2:S142-S147. PMC: 6822377. DOI: 10.1097/QAI.0000000000002179. View

Shah A, Hayes C, Martin B . Characteristics of Initial Prescription Episodes and Likelihood of Long-Term Opioid Use - United States, 2006-2015. MMWR Morb Mortal Wkly Rep. 2017; 66(10):265-269. PMC: 5657867. DOI: 10.15585/mmwr.mm6610a1. View

Von Korff M, Scher A, Helmick C, Carter-Pokras O, Dodick D, Goulet J . United States National Pain Strategy for Population Research: Concepts, Definitions, and Pilot Data. J Pain. 2016; 17(10):1068-1080. DOI: 10.1016/j.jpain.2016.06.009. View

Davis C, Carr D . Physician continuing education to reduce opioid misuse, abuse, and overdose: Many opportunities, few requirements. Drug Alcohol Depend. 2016; 163:100-7. DOI: 10.1016/j.drugalcdep.2016.04.002. View

Cerda M, Wheeler-Martin K, Bruzelius E, Ponicki W, Gruenewald P, Mauro C . Spatiotemporal Analysis of the Association Between Pain Management Clinic Laws and Opioid Prescribing and Overdose Deaths. Am J Epidemiol. 2021; 190(12):2592-2603. PMC: 8796812. DOI: 10.1093/aje/kwab192. View

Schuler M, Heins S, Smart R, Griffin B, Powell D, Stuart E . The state of the science in opioid policy research. Drug Alcohol Depend. 2020; 214:108137. PMC: 7423757. DOI: 10.1016/j.drugalcdep.2020.108137. View

10.

Chiu A, Jean R, Hoag J, Freedman-Weiss M, Healy J, Pei K . Association of Lowering Default Pill Counts in Electronic Medical Record Systems With Postoperative Opioid Prescribing. JAMA Surg. 2018; 153(11):1012-1019. PMC: 6583068. DOI: 10.1001/jamasurg.2018.2083. View

11.

Schuler M, Griffin B, Cerda M, McGinty E, Stuart E . Methodological Challenges and Proposed Solutions for Evaluating Opioid Policy Effectiveness. Health Serv Outcomes Res Methodol. 2021; 21(1):21-41. PMC: 8057700. DOI: 10.1007/s10742-020-00228-2. View

12.

Graetz I, Yarbrough C, Hu X, Howard D . Association of Mandatory-Access Prescription Drug Monitoring Programs With Opioid Prescriptions Among Medicare Patients Treated by a Medical or Hematologic Oncologist. JAMA Oncol. 2020; 6(7):1102-1103. PMC: 7206528. DOI: 10.1001/jamaoncol.2020.0804. View

13.

Lee B, Zhao W, Yang K, Ahn Y, Perry B . Systematic Evaluation of State Policy Interventions Targeting the US Opioid Epidemic, 2007-2018. JAMA Netw Open. 2021; 4(2):e2036687. PMC: 7881356. DOI: 10.1001/jamanetworkopen.2020.36687. View

15.

Sacks D, Hollingsworth A, Nguyen T, Simon K . Can policy affect initiation of addictive substance use? Evidence from opioid prescribing. J Health Econ. 2020; 76:102397. PMC: 8588877. DOI: 10.1016/j.jhealeco.2020.102397. View

16.

Cotton B, Lohman M, Brooks J, Whiteman K, Bao Y, Greenberg R . Prevalence of and Factors Related to Prescription Opioids, Benzodiazepines, and Hypnotics Among Medicare Home Health Recipients. Home Healthc Now. 2017; 35(6):304-313. PMC: 5505646. DOI: 10.1097/NHH.0000000000000553. View

17.

Tian T, Zlateva I, Anderson D . Using electronic health records data to identify patients with chronic pain in a primary care setting. J Am Med Inform Assoc. 2013; 20(e2):e275-80. PMC: 3861913. DOI: 10.1136/amiajnl-2013-001856. View

18.

Owen-Smith A, Ahmedani B, Peterson E, Simon G, Rossom R, Lynch F . The Mediating Effect of Sleep Disturbance on the Relationship Between Nonmalignant Chronic Pain and Suicide Death. Pain Pract. 2018; 19(4):382-389. PMC: 6818648. DOI: 10.1111/papr.12750. View

19.

Janakiram C, Fontelo P, Huser V, Chalmers N, Mitnik G, Brow A . Opioid Prescriptions for Acute and Chronic Pain Management Among Medicaid Beneficiaries. Am J Prev Med. 2019; 57(3):365-373. PMC: 6713282. DOI: 10.1016/j.amepre.2019.04.022. View